ArticleOPEN ACCESS

Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia (Signal Transduction and Targeted Therapy, (2022), 7, 1, (51), 10.1038/s41392-021-00870-3)

Signal Transduction and Targeted Therapy
DOI: 10.1038/s41392-022-00958-4
3Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In the original version of this article, given name of 4th author Yannan Jia was incorrectly published as Yanan Jia. The original article has been corrected.

Cite

CITATION STYLE

APA

Zhang, Q., Riley-Gillis, B., Han, L., Jia, Y., Lodi, A., Zhang, H., … Konopleva, M. (2022, December 1). Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia (Signal Transduction and Targeted Therapy, (2022), 7, 1, (51), 10.1038/s41392-021-00870-3). Signal Transduction and Targeted Therapy. Springer Nature. https://doi.org/10.1038/s41392-022-00958-4

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free